JPMorgan Chase has hired Jane Wu, former Chief Investment Officer of healthcare-focused hedge fund Springhill Fund Asset Management, to head its China healthcare investment banking franchise, as capital markets activity in the sector accelerates, according to a report by Bloomberg.
Wu, who will be based in Hong Kong from 29 September, brings more than a decade of experience investing in Asian healthcare, having held senior roles at Fidelity Management & Research and Qiming Venture Partners’ Springhill unit, where she oversaw a portfolio that at its peak managed $550m.
Her appointment comes amid a resurgence in Chinese healthcare deal-making. APAC healthcare-related equity offerings have already raised $17.5bn in 2025, outpacing the previous two years combined, according to Bloomberg data. Cross-border licensing deals are also increasing, with Chinese biotech firms striking high-value partnerships with US and European pharma groups.
For private equity and venture investors, the rebound underscores the importance of seasoned sector specialists like Wu, who have navigated both public and private healthcare markets through volatility. The MSCI China Healthcare Index has surged 80% over the past 12 months, though valuations remain well below 2021 highs, creating potential entry points for private capital.
Springhill, where Wu most recently served as CIO, was launched in 2021 by Qiming Venture Partners as a public equities arm, investing in over 150 Chinese healthcare companies. Despite fundraising challenges amid Covid-19 restrictions and geopolitical tensions, the fund gained visibility as part of a new wave of women-led hedge fund managers.
